Free Webinar to Address Collaborative Quality Improvement for Monitoring Outcomes in Thyroid, Parathyroid, Adrenal and Neuroendocrine Surgery

March 19, 2014

Presentation from International Authority on Minimally Invasive Endocrine Surgery to Focus on Enhancing Patient Safety through Outcomes Analysis

ANN ARBOR, Mich., March 19, 2014 /PRNewswire/ — William B. Inabnet III, M.D., FACS, an internationally recognized authority in the field of minimally invasive endocrine surgery, will present a free webinar on Wednesday, March 26(th), on enhancing patient safety with outcomes analysis through the Collaborative Endocrine Surgery Quality Improvement Program (CESQIP).


The webinar, which is open to all healthcare executives, administrators and clinicians, is titled “CESQIP: A Dynamic Quality Improvement Initiative for Monitoring Outcomes in Thyroid, Parathyroid, Adrenal and Neuroendocrine Surgery.”

The live one-hour webinar begins at 4 p.m. EDT and will include a question and answer period. Brett Furst, the CEO of ArborMetrix, Inc., a leading provider of real-time healthcare analytics, will be the moderator for the webinar. Please register through this link.

An international authority in the field of minimally invasive endocrine surgery, Dr Inabnet has pioneered new techniques in minimal access endocrine neck surgery as well as adrenal and pancreatic surgery. In 1998, he helped perform the first endoscopic thyroid resection in the United States and has helped advance the field of video-endoscopic neck surgery.

Designed by endocrine surgeons to be inclusive and easy to use, CESQIP is accessible, accurate, and cost-effective. Dr. Inabnet will demonstrate and discuss the benefits of participating in CESQIP, a cloud-based quality improvement initiative that allows surgeons, programs and institutions to monitor their outcomes in thyroid, parathyroid, adrenal, and pancreatic/neuroendocrine procedures.

In this webinar, attendees will learn:

    --  How CESQIP uses continuous quality improvement to view outcomes through
        patient-centered data collection, with ongoing performance feedback.
    --  How CESQIP uses collaborative learning and real-time reporting to
        provide flexible and protected data access, further enabling the
        transition to shared accountability care/payment models.
    --  How patient safety is enhanced through CESQIP's best practices, decision
        support, and care pathways.
    --  How CESQIP is being used as an innovative platform for multidisciplinary
        collaboration at the regional, national and international levels by
        providing defined, true long-term outcome analysis.

Dr. Inabnet is the Eugene W Friedman Professor of Surgery, Chief of Metabolic, Endocrine and Minimally Invasive Surgery and Surgical Director of the Diabetes, Obesity and Metabolism Institute at the Icahn School of Medicine at Mount Sinai. Dr Inabnet completed a fellowship in endocrine surgery at Cochin Hospital in Paris, France, where he trained under Professor Yves Chapuis, a world leader in the field of endocrine surgery and targeted parathyroidectomy.

Click to Tweet: #Physicians, catch this Webinar on Mar. 26 by William Inabnet III, MD on #analytics, #patientsafety & #qualitycare. http://bit.ly/1gH1LuX

About ArborMetrix

ArborMetrix, Inc., located in Ann Arbor, Michigan, provides a unique, cloud-based platform for performance measurement and clinical intelligence in acute and specialty care. Based on its industry changing econometric research, ArborMetrix solutions deliver rigorous data analysis and actionable business intelligence while incorporating advanced risk and reliability adjustments. With valuable insights grounded in clinical evidence, ArborMetrix clients quickly achieve quality improvements and cost savings. For more information, visit www.arbormetrix.com, email info@arbormetrix.com or call 734-661-7944, ext. 7008.

Media Contact:

Amendola Communications for ArborMetrix

Tim Boivin, 224-209-6495


Logo – http://photos.prnewswire.com/prnh/20140217/MM66640LOGO

SOURCE ArborMetrix, Inc.

Source: PR Newswire

comments powered by Disqus